Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review

Bimekizumab is the most recent interleukin (IL)-17 inhibitors (IL-17i) approved for plaque psoriasis in adult patients. Despite biologic switching being common in routine clinical practice, evidence remains sparse regarding switching within class from another IL-17i to bimekizumab. We conducted a real-world study of bimekizumab use in patients with prior IL-17i exposure.